
PubMed:7903907
Annnotations
DisGeNET
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T0 | 89-98 | gene:2064 | denotes | HER-2/neu |
T1 | 125-138 | disease:C0678222 | denotes | breast cancer |
T2 | 89-98 | gene:2064 | denotes | HER-2/neu |
T3 | 125-138 | disease:C0006142 | denotes | breast cancer |
T11 | 202-215 | disease:C0006142 | denotes | breast cancer |
T10 | 180-189 | gene:2064 | denotes | HER-2/neu |
T9 | 202-215 | disease:C0678222 | denotes | breast cancer |
T8 | 180-189 | gene:2064 | denotes | HER-2/neu |
T7 | 202-215 | disease:C0006142 | denotes | breast cancer |
T6 | 242-259 | gene:2099 | denotes | estrogen receptor |
T5 | 202-215 | disease:C0678222 | denotes | breast cancer |
T4 | 242-259 | gene:2099 | denotes | estrogen receptor |
R1 | T0 | T1 | associated_with | HER-2/neu,breast cancer |
R2 | T2 | T3 | associated_with | HER-2/neu,breast cancer |
R3 | T4 | T5 | associated_with | estrogen receptor,breast cancer |
R4 | T6 | T7 | associated_with | estrogen receptor,breast cancer |
R5 | T8 | T9 | associated_with | HER-2/neu,breast cancer |
R6 | T10 | T11 | associated_with | HER-2/neu,breast cancer |
jnlpba-st-training
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T1 | 89-107 | DNA | denotes | HER-2/neu oncogene |
T2 | 180-198 | DNA | denotes | HER-2/neu oncogene |
T3 | 242-259 | protein | denotes | estrogen receptor |
T4 | 386-395 | protein | denotes | HER-2/neu |
T5 | 549-558 | protein | denotes | HER-2/neu |
T6 | 614-628 | cell_line | denotes | K562 cell line |
T7 | 659-683 | cell_type | denotes | natural killer (NK) cell |
T8 | 735-742 | cell_type | denotes | NK cell |
T9 | 805-818 | cell_type | denotes | benign tumors |
T10 | 947-964 | protein | denotes | HER-2/neu protein |
T11 | 997-1004 | cell_type | denotes | NK cell |
T12 | 1087-1096 | protein | denotes | HER-2/neu |
T13 | 1130-1137 | cell_type | denotes | NK cell |
T14 | 1181-1190 | protein | denotes | HER-2/neu |
T15 | 1304-1313 | protein | denotes | HER-2/neu |
T16 | 1355-1364 | protein | denotes | HER-2/neu |
T17 | 1407-1424 | protein | denotes | estrogen receptor |
pubmed-sentences-benchmark
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
S1 | 0-139 | Sentence | denotes | Increased natural killer cell activity correlates with low or negative expression of the HER-2/neu oncogene in patients with breast cancer. |
S2 | 140-151 | Sentence | denotes | BACKGROUND: |
S3 | 152-321 | Sentence | denotes | Increased expression of the HER-2/neu oncogene in breast cancer correlates with decreased estrogen receptor concentration and seems to be an important prognostic factor. |
S4 | 322-492 | Sentence | denotes | The authors investigated whether there is a correlation between HER-2/neu expression and immunologic parameters representing tumor defense in patients with breast cancer. |
S5 | 493-500 | Sentence | denotes | METHOD: |
S6 | 501-693 | Sentence | denotes | A Western blot analysis was used to investigate HER-2/neu expression, whereas a chromium-release assay using the K562 cell line as target was used to measure natural killer (NK) cell activity. |
S7 | 694-702 | Sentence | denotes | RESULTS: |
S8 | 703-871 | Sentence | denotes | In patients with breast cancer, NK cell activity was significantly higher compared with patients with benign tumors (P = 0.006) or healthy control subjects (P = 0.002). |
S9 | 872-965 | Sentence | denotes | Moreover, 23.3% of patients with breast cancer showed an overexpression of HER-2/neu protein. |
S10 | 966-1129 | Sentence | denotes | Within this group of patients, NK cell activity was significantly lower (45.6 +/- 16.1%) compared with the group with no HER-2/neu overexpression (57.3 +/- 11.0%). |
S11 | 1130-1206 | Sentence | denotes | NK cell activity did not increase in patients with HER-2/neu overexpression. |
S12 | 1207-1444 | Sentence | denotes | Thus, there was a statistically significant correlation of cytolytic effector cell function with HER-2/neu expression of the tumor (P = 0.003), and HER-2/neu overexpression correlated with a negative estrogen receptor status (P = 0.005). |
S13 | 1445-1456 | Sentence | denotes | CONCLUSION: |
S14 | 1457-1642 | Sentence | denotes | These data add further evidence to previous observations from the authors' laboratory that certain tumor characteristics may be associated with reactions of the host with breast cancer. |
genia-medco-coref
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
C1 | 10-38 | NP | denotes | natural killer cell activity |
C4 | 111-138 | NP | denotes | patients with breast cancer |
C3 | 85-138 | NP | denotes | the HER-2/neu oncogene in patients with breast cancer |
C2 | 55-138 | NP | denotes | low or negative expression of the HER-2/neu oncogene in patients with breast cancer |
C5 | 176-215 | NP | denotes | the HER-2/neu oncogene in breast cancer |
C6 | 386-406 | NP | denotes | HER-2/neu expression |
C7 | 464-491 | NP | denotes | patients with breast cancer |
C8 | 549-569 | NP | denotes | HER-2/neu expression |
C9 | 659-692 | NP | denotes | natural killer (NK) cell activity |
C10 | 706-733 | NP | denotes | patients with breast cancer |
C11 | 735-751 | NP | denotes | NK cell activity |
C12 | 882-918 | NP | denotes | 23.3% of patients with breast cancer |
C13 | 926-964 | NP | denotes | an overexpression of HER-2/neu protein |
C14 | 973-995 | NP | denotes | this group of patients |
C15 | 997-1013 | NP | denotes | NK cell activity |
C16 | 1130-1146 | NP | denotes | NK cell activity |
C18 | 1181-1205 | NP | denotes | HER-2/neu overexpression |
C17 | 1167-1205 | NP | denotes | patients with HER-2/neu overexpression |
C19 | 1304-1324 | NP | denotes | HER-2/neu expression |
C20 | 1355-1379 | NP | denotes | HER-2/neu overexpression |
C21 | 1492-1542 | NP | denotes | previous observations from the authors' laboratory |
C22 | 1543-1547 | NP | denotes | that |
C23 | 1614-1641 | NP | denotes | the host with breast cancer |
R1 | C5 | C3 | coref-ident | the HER-2/neu oncogene in breast cancer,the HER-2/neu oncogene in patients with breast cancer |
R2 | C6 | C2 | coref-other | HER-2/neu expression,low or negative expression of the HER-2/neu oncogene in patients with breast cancer |
R3 | C7 | C4 | coref-ident | patients with breast cancer,patients with breast cancer |
R4 | C8 | C6 | coref-ident | HER-2/neu expression,HER-2/neu expression |
R5 | C9 | C1 | coref-ident | natural killer (NK) cell activity,natural killer cell activity |
R6 | C10 | C7 | coref-ident | patients with breast cancer,patients with breast cancer |
R7 | C11 | C9 | coref-ident | NK cell activity,natural killer (NK) cell activity |
R8 | C12 | C10 | coref-part-whole | 23.3% of patients with breast cancer,patients with breast cancer |
R9 | C14 | C12 | coref-ident | this group of patients,23.3% of patients with breast cancer |
R10 | C15 | C11 | coref-ident | NK cell activity,NK cell activity |
R11 | C16 | C15 | coref-ident | NK cell activity,NK cell activity |
R12 | C18 | C13 | coref-ident | HER-2/neu overexpression,an overexpression of HER-2/neu protein |
R13 | C17 | C12 | coref-ident | patients with HER-2/neu overexpression,23.3% of patients with breast cancer |
R14 | C19 | C6 | coref-ident | HER-2/neu expression,HER-2/neu expression |
R15 | C22 | C21 | coref-relat | that,previous observations from the authors' laboratory |
R16 | C23 | C10 | coref-ident | the host with breast cancer,patients with breast cancer |
GENIAcorpus
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T1 | 10-38 | other_name | denotes | natural killer cell activity |
T2 | 89-107 | DNA_domain_or_region | denotes | HER-2/neu oncogene |
T3 | 111-119 | multi_cell | denotes | patients |
T4 | 125-138 | other_name | denotes | breast cancer |
T5 | 180-198 | DNA_domain_or_region | denotes | HER-2/neu oncogene |
T6 | 202-215 | other_name | denotes | breast cancer |
T7 | 242-250 | lipid | denotes | estrogen |
T8 | 386-395 | protein_molecule | denotes | HER-2/neu |
T9 | 411-433 | other_name | denotes | immunologic parameters |
T10 | 464-472 | multi_cell | denotes | patients |
T11 | 478-491 | other_name | denotes | breast cancer |
T12 | 503-524 | other_name | denotes | Western blot analysis |
T13 | 549-558 | protein_molecule | denotes | HER-2/neu |
T14 | 581-603 | other_name | denotes | chromium-release assay |
T15 | 614-628 | cell_line | denotes | K562 cell line |
T16 | 659-683 | cell_type | denotes | natural killer (NK) cell |
T17 | 706-714 | multi_cell | denotes | patients |
T18 | 720-733 | other_name | denotes | breast cancer |
T19 | 735-742 | cell_type | denotes | NK cell |
T20 | 791-799 | multi_cell | denotes | patients |
T21 | 805-818 | cell_type | denotes | benign tumors |
T22 | 834-858 | multi_cell | denotes | healthy control subjects |
T23 | 891-899 | multi_cell | denotes | patients |
T24 | 905-918 | other_name | denotes | breast cancer |
T25 | 947-956 | protein_molecule | denotes | HER-2/neu |
T26 | 987-995 | multi_cell | denotes | patients |
T27 | 997-1004 | cell_type | denotes | NK cell |
T28 | 1087-1096 | protein_molecule | denotes | HER-2/neu |
T29 | 1130-1137 | cell_type | denotes | NK cell |
T30 | 1167-1175 | multi_cell | denotes | patients |
T31 | 1181-1190 | protein_molecule | denotes | HER-2/neu |
T32 | 1304-1313 | protein_molecule | denotes | HER-2/neu |
T33 | 1355-1364 | protein_molecule | denotes | HER-2/neu |
T34 | 1407-1415 | lipid | denotes | estrogen |
T35 | 1556-1577 | other_name | denotes | tumor characteristics |
T36 | 1628-1641 | other_name | denotes | breast cancer |